A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed
暂无分享,去创建一个
Thomas C. Chen | A. Schönthal | Thomas C Chen | V. Schijns | H. Linardou | D. Blumenthal | D. Bota | S. Singer | F. Senecal | B. Fu | X. Kong | Thomas H. Taylor | Naomi Lomeli | E. Rokas | Dimitris G. Antoniou | J. Elliot | A. Stathopoulos
[1] Pieter Wesseling,et al. cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading , 2020, Brain pathology.
[2] K. Schalper,et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma , 2019, Nature Medicine.
[3] E. Kirson,et al. Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune® System , 2019, Clinical Medicine Insights. Oncology.
[4] P. Wen,et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.
[5] Thomas C. Chen,et al. Therapeutic Immunization against Glioblastoma , 2018, International journal of molecular sciences.
[6] A. Schönthal,et al. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts , 2018, CNS oncology.
[7] M. Weller,et al. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] F. Lieberman,et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.
[9] Martin Klein,et al. Lomustine and Bevacizumab in Progressive Glioblastoma , 2017, The New England journal of medicine.
[10] A. Brandes,et al. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. , 2016, Neuro-oncology.
[11] A. Brandes,et al. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. , 2016, Neuro-oncology.
[12] Juanita Lopez,et al. Immuno-oncology combinations: raising the tail of the survival curve , 2016, Cancer biology & medicine.
[13] A. Weyerbrock,et al. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine , 2016, Journal of Neuro-Oncology.
[14] J. Simes,et al. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. , 2015, Neuro-oncology.
[15] Peter Hantos,et al. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. , 2015, Vaccine.
[16] Thomas C Chen,et al. Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. , 2015, The Permanente journal.
[17] R. Vernhout,et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.
[18] T. Mikkelsen,et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Baehring,et al. Faculty Opinions recommendation of NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. , 2012 .
[20] P. Gutin,et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. , 2012, European journal of cancer.
[21] W. Mason,et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Trippel,et al. BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors , 2010, BMC Cancer.
[23] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] John A Butman,et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Timothy F Cloughesy,et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. , 2008, Neuro-oncology.
[26] Thomas C Chen,et al. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat. , 2008, Vaccine.
[27] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.
[28] H. Sutton. AN EPIDEMIOLOGICAL STUDY , 1937 .
[29] J. Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. , 2019, Neuro-oncology.
[30] A. Brandes,et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. , 2019, The Lancet. Oncology.
[31] A. Stathopoulos. Therapeutic brain cancer targeting by gene therapy and immunomodulation : a translational study , 2012 .
[32] M. Chamberlain,et al. Salvage therapy with single agent bevacizumab for recurrent glioblastoma , 2009, Journal of Neuro-Oncology.
[33] E. Glaser. The randomized clinical trial. , 1972, The New England journal of medicine.